

Kevin P Hill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276429/publications.pdf>

Version: 2024-02-01

45
papers

1,399
citations

516215

16
h-index

344852

36
g-index

47
all docs

47
docs citations

47
times ranked

1976
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. JAMA - Journal of the American Medical Association, 2015, 313, 2474.	3.8	419
2	Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2017, 2, 96-104.	1.5	172
3	The ADVANTAGE Seeding Trial: A Review of Internal Documents. Annals of Internal Medicine, 2008, 149, 251.	2.0	113
4	Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug and Alcohol Dependence, 2014, 145, 121-126.	1.6	90
5	Clinical uses of cannabis and cannabinoids in the United States. Journal of the Neurological Sciences, 2020, 411, 116717.	0.3	60
6	Medical Use of Cannabis in 2019. JAMA - Journal of the American Medical Association, 2019, 322, 974.	3.8	49
7	Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. American Journal on Addictions, 2017, 26, 795-801.	1.3	42
8	Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal of Psychiatry, 2022, 179, 98-109.	4.0	42
9	Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. Journal of General Internal Medicine, 2021, 36, 2074-2084.	1.3	40
10	Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Dual Nicotine and Cannabis Dependence: A Pilot Study. American Journal on Addictions, 2013, 22, 233-238.	1.3	36
11	Denosing scanner effects from multimodal MRI data using linked independent component analysis. NeuroImage, 2020, 208, 116388.	2.1	32
12	Cannabis and Mood Disorders. Current Addiction Reports, 2018, 5, 336-345.	1.6	30
13	Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders. JAMA - Journal of the American Medical Association, 2017, 317, 1070.	3.8	28
14	Cannabinoids and the Coronavirus. Cannabis and Cannabinoid Research, 2020, 5, 118-120.	1.5	26
15	Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug and Alcohol Dependence, 2013, 132, 342-345.	1.6	24
16	Priority Considerations for Medicinal Cannabis-Related Research. Cannabis and Cannabinoid Research, 2019, 4, 139-157.	1.5	21
17	Biological Treatments for Amphetamine Dependence. CNS Drugs, 2007, 21, 851-869.	2.7	16
18	The Role of Cannabis Legalization in the Opioid Crisis. JAMA Internal Medicine, 2018, 178, 679.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Medical Marijuana. <i>Journal of Psychiatric Practice</i> , 2014, 20, 389-391.	0.3	14
20	Cannabis Legalization and Psychiatric Disorders: Caveat "Hemp-tor". <i>Canadian Journal of Psychiatry</i> , 2018, 63, 447-450.	0.9	14
21	Minimal Physical Health Risk Associated With Long-term Cannabis Use "But Buyer Beware. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2338.	3.8	13
22	Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science. <i>Pain Medicine</i> , 2019, 20, 2311-2323.	0.9	13
23	Review: Non-Invasive Brain Stimulation in Behavioral Addictions: Insights from Direct Comparisons With Substance Use Disorders. <i>American Journal on Addictions</i> , 2019, 28, 431-454.	1.3	12
24	Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series. <i>Journal of Opioid Management</i> , 2015, 11, 363-366.	0.2	11
25	Cannabis legalisation in Canada: a crucial trial balloon. <i>Lancet Psychiatry</i> , the, 2019, 6, 5-6.	3.7	10
26	Cannabis and the Current State of Treatment for Cannabis Use Disorder. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	8
27	What gets resident physicians stressed and how would they prefer to be supported? A best "worst scaling study. <i>Postgraduate Medical Journal</i> , 2022, 98, 930-935.	0.9	7
28	Behavioral Interventions and Pharmacotherapies for Cannabis Use Disorder. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 163-174.	0.7	5
29	Therapeutic cannabis use in 2018: where do we stand?. <i>Lancet Psychiatry</i> , the, 2019, 6, 88-89.	3.7	5
30	Workplace Cannabis Policies: A Moving Target. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 16-23.	1.5	5
31	Recreational cannabis legalisation: details will determine mental health effects. <i>Lancet Psychiatry</i> , the, 2016, 3, 798-799.	3.7	4
32	How Emergency Physicians Approach Refusal of Observation after Naloxone Resuscitation. <i>Journal of Emergency Medicine</i> , 2020, 58, 148-159.	0.3	4
33	Care of the Patient Using Cannabis. <i>Annals of Internal Medicine</i> , 2020, 173, ITC65-ITC80.	2.0	3
34	The Molecular-Container Calabadion-2 Prevents Methamphetamine-Induced Reinstatement in Rats: A Potential Approach to Relapse Prevention?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 401-405.	1.0	3
35	A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics. <i>Journal of Cannabis Research</i> , 2021, 3, 23.	1.5	3
36	Teaching Residents to Treat Substance Use Disorders: Overcoming 10 Common Patient-Perceived Barriers to Outpatient Treatment Engagement. <i>Academic Psychiatry</i> , 2021, 45, 217-221.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Diagnosing and treating opioid dependence. <i>Journal of Family Practice</i> , 2012, 61, 588-97.	0.2	2
38	Medical marijuana does not increase adolescent marijuana use. <i>Lancet Psychiatry</i> , 2015, 2, 572-573.	3.7	1
39	Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry. <i>American Journal on Addictions</i> , 2020, 29, 401-406.	1.3	1
40	Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?. <i>Annals of Internal Medicine</i> , 2021, 174, 237-246.	2.0	1
41	Buprenorphine in safety-sensitive positions. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, , 1-5.	1.1	1
42	Reply: Response to Letter to the Editor. <i>Neuropsychopharmacology</i> , 2008, 33, 2044-2044.	2.8	0
43	Commentary: Proposed Model State Cannabis Laws to Reduce Harms. <i>American Journal on Addictions</i> , 2020, 29, 426-427.	1.3	0
44	Self-Reported Preferences for Help-Seeking and Barriers to Using Mental Health Supports Among Internal Medicine Residents: Exploratory Use of an Econometric Best-Worst Scaling Framework for Gathering Physician Wellness Preferences. <i>JMIR Medical Education</i> , 2021, 7, e28623.	1.2	0
45	After detoxification: levels of treatment for alcohol dependence. <i>American Family Physician</i> , 2013, 88, 576.	0.1	0